New Key Statistics Module, Z-Score and F-Score
NAS:TARS Key Ratios
| Market Cap $ M | 2,102.48 |
| Enterprise Value $ M | 1,833.02 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 8.84 |
| Price/Sales | 15.55 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 129.00 |
| EPS (TTM) $ | -3.81 |
| Beneish M-Score | 4.04 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -42.00 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -14.31 |
| EV-to-EBITDA | -14.44 |
| PEG | -- |
| Shares Outstanding M | 38.23 |
| Net Margin (%) | -103.64 |
| Operating Margin % | -108.47 |
| Pre-tax Margin (%) | -103.64 |
| Quick Ratio | 5.38 |
| Current Ratio | 5.42 |
| ROA % (ttm) | -41.05 |
| ROE % (ttm) | -57.14 |
| ROIC % (ttm) | -1,114.97 |
| Dividend Yield % | -- |
| Altman Z-Score | 7.88 |
TARS Number of Guru Trades
TARS Volume of Guru Trades
Gurus Latest Trades with NAS:TARS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:TARS is held by these investors
Total 1
Tarsus Pharmaceuticals Inc Insider Transactions
No Available Data
News about NAS:TARS
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers